Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure

Nature Reviews Cardiology volume 19, pages 499–500 (2022)Cite this article

Subjects

The totality of evidence from large-scale, randomized, controlled clinical trials and mechanistic studies in the laboratory has provided six crucial lessons about the emerging role of SGLT2 inhibitors to prevent the onset of heart failure in patients at high risk and slow the progression of heart failure in patients with established disease.

Sodium–glucose cotransporter 2 (SGLT2) inhibitors prevent the onset of heart failure in patients at high risk and slow the progression of heart failure in patients with established disease. The concordance of evidence from multiple large-scale clinical trials has strengthened our understanding of the role of these drugs and underscored several remaining questions. This Clinical Outlook article highlights six main conclusions from our experience of using these drugs in patients with heart failure (Box 1).

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Giugliano, D. et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc. Diabetol. 20, 236 (2021).

    CAS  Article  Google Scholar 

  2. Packer, M. et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur. Heart J. 42, 671–680 (2021).

    CAS  Article  Google Scholar 

  3. Usman, M. S. et al. Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. ESC Heart Fail. 9, 885–893 (2022).

    Article  Google Scholar 

  4. Packer, M. Does a target dose or a target heart rate matter to outcomes when prescribing β-blockers to patients with chronic heart failure? Circ. Cardiovasc. Qual. Outcomes 11, e004605 (2018).

    Article  Google Scholar 

  5. Packer, M. & McMurray, J. J. V. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur. J. Heart Fail. 23, 882–894 (2021).

    CAS  Article  Google Scholar 

  6. Shen, L. et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 9, 254–264 (2021).

    Article  Google Scholar 

  7. Vaduganathan, M. et al. Estimating the benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction. Circulation https://doi.org/10.1161/CIRCULATIONAHA.121.058929 (2022).

    Article  PubMed  Google Scholar 

  8. Butler, J. et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur. Heart J. 43, 416–426 (2022).

    CAS  Article  Google Scholar 

  9. Packer, M. et al. Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. Eur. J. Heart Fail. 23, 1798–1799 (2021).

    CAS  Article  Google Scholar 

  10. Packer, M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation 141, 2095–2105 (2020).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor Heart and Vascular Institute, Dallas, TX, USA

    Milton Packer

  2. Imperial College, London, UK

    Milton Packer

Authors
  1. Milton Packer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Milton Packer.

Ethics declarations

Competing interests

M.P. has received consulting fees from AbbVie, Actavis, Altimmune, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Imara, Lilly, Moderna, Novartis, Reata, Relypsa and Salamandra. M.P. has no current or planned financial relationships related to SGLT2 inhibitors or neprilysin inhibition.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Packer, M. Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure. Nat Rev Cardiol 19, 499–500 (2022). https://doi.org/10.1038/s41569-022-00736-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-022-00736-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing